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Approval of chronic medication –  
Discovery Health hits new lows
To the Editor: I was asked to see a patient with poorly 
controlled hypertension and a strong family history of type 2 
diabetes. In June 2010, glucometer readings were consistently 
raised (approximately 18 mmol/l) and his general practitioner 
did an HBA1C, which was markedly elevated at 10.9. A 
diagnosis of type 2 diabetes was made and he was commenced 
on metformin. A fasting lipogram showed significant 
dyslipidaemia consistent with metabolic syndrome.
After adjusting his antihypertensive treatment, I completed 
his chronic medication forms, which included metformin. I 
received a faxed reply from Dr Andrew Murray saying that 
his HBA1C was not considered diagnostic for type 2 diabetes, 
and benefits for metformin were denied because there was no 
documented laboratory glucose. I wrote to Dr Errol Gottlich, 
who has helped me in the past with this type of issue. I 
pointed out that the American Diabetes Association now 
considers HBA1C a diagnostic test for diabetes (HBA1C >6.5) 
and, furthermore, with a level of 10.9, there was no alternative 
diagnosis.
I learnt from Dr Gottlich that Dr Murray was in China, and 
he would forward my email to the relevant department. Dr 
Ndlovu telephoned and still refused to approve metformin, 
based on the fact that I had not proved the diagnosis because 
Discovery did not recognise HBA1C as a diagnostic test. I again 
explained that, as a professor of medicine, I could surely make 
a diagnosis of type 2 diabetes and understood the diagnostic 
criteria, but he still refused to back down.
I am sure many readers are familiar with this sort of situation 
and have similar frustrations. I was personally insulted by the 
arrogance of the advisor. I am intelligent enough to understand 
there is a need for medical aids to ensure that the diagnosis of 
type 2 diabetes is established correctly to avoid over-servicing 
but, when discussing an individual patient with a very senior 
academic and colleague, you would think that the advisor 
would use his discretion instead of following a mindless 
bureaucratic protocol.
Fortunately this patient can afford to continue his metformin 
out of his own pocket for the time being, but many patients do 
not have the resources to do this and suffer the consequences 
of uncontrolled diabetes.
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